New Level-Up Data: Upadacitinib Shows Superiority Over Dupilumab for All Ranked Secondary End Points in Head-to-head AD Study
Upadacitinib (Rinvoq, AbbVie) bested dupilumab (Dupixent, Sanofi & Regeneron) for all ranked secondary endpoints including complete skin clearance and rapid resolution of itching in Level-Up, a phase 3b/4 head-to-head study comparing the two therapies in atopic dermatitis (AD). The findings, presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago, IL, build on […]